Core Points - Bid Pharma (688073) announced a plan for its controlling shareholder, Dai Lan, to reduce his stake in the company due to personal financial needs [1] - The reduction will occur within three months after the disclosure of the plan, with a maximum of 148,800 shares to be sold, representing 0.16% of the total share capital [1] - Dai Lan currently holds 29,664,700 shares, accounting for 32.64% of the total shares of Bid Pharma [1]

Core Viewpoint - Bid Pharma (688073.SH) announced that its controlling shareholder, actual controller, chairman, and general manager, Dai Lan, plans to reduce his shareholding within three months after the disclosure of the reduction plan, depending on market conditions [1] Summary by Sections - **Shareholding Reduction Plan** - Dai Lan intends to reduce his holdings through centralized bidding transactions, with a maximum reduction of 148,800 shares, which accounts for 0.16% of the company's total share capital [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1]

Core Viewpoint - Bid Pharma announced that its controlling shareholder, Ms. Dai Lan, plans to reduce her shareholding in the company due to personal financial needs, with a maximum reduction of 148,835 shares, representing 0.16% of the total share capital [1] Group 1 - The reduction plan will commence 15 trading days after the announcement and will be executed within a three-month period [1] - The shares will be sold through centralized bidding on the market [1] - The selling price will be determined based on the market price at the time of the actual reduction [1]

Core Viewpoint - Bid Pharma (688073.SH) announced a plan for its controlling shareholder and actual controller, Dai Lan, to reduce his shareholding in the company due to personal funding needs [1] Group 1 - The reduction plan will be executed through centralized bidding transactions within three months after the disclosure of the reduction plan, starting from 15 trading days thereafter [1] - The maximum number of shares to be reduced is 148,800 shares, which accounts for no more than 0.16% of the company's total share capital [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1]

Core Viewpoint - Bid Pharma (688073.SH) announced that its controlling shareholder, actual controller, and company chairman and general manager, Ms. Dai Lan, plans to reduce her shareholding due to personal funding needs, with a maximum reduction of 148,800 shares, accounting for 0.16% of the company's total share capital [1] Summary by Sections - Shareholding Reduction Plan - Ms. Dai Lan intends to reduce her shareholding through centralized bidding transactions starting 15 trading days after the announcement, within a period of three months [1] - The maximum number of shares to be reduced is 148,800, which represents 0.16% of the total share capital of the company [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1]

上海毕得医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688073 证券简称：毕得医药 公告编号：2025-088 股东持股的基本情况 截至本公告披露之日，上海毕得医药科技股份有限公司（以下简称"毕得医 药"或"公司"）控股股东、实际控制人兼公司董事长、总经理戴岚女士持有公 司股份 29,664,719 股，占公司股份总数的 32.64%，其中 29,515,884 股为有限售 条件流通股，148,835 股为无限售条件流通股。 戴岚女士所持股份中，21,082,774 股来源为公司首次公开发行并上市前取得 的股份，8,433,110 股为前述股份因公司权益分派由资本公积转增取得的股份， 另外 148,835 股为集中竞价交易取得的股份。 减持计划的主要内容 因自身资金需要，戴岚女士计划根据市场情况拟于本减持计划披露之日起 15 个交易日后的 3 个月内通过集中竞价交易方式减持其通过二级市场集中竞价 交易取得的公司股份，减持数量不超过 14 ...

格隆汇11月25日丨毕得医药(688073.SH)公布，因自身资金需要，控股股东、实际控制人兼公司董事 长、总经理戴岚女士计划根据市场情况拟于本减持计划披露之日起15个交易日后的3个月内通过集中竞 价交易方式减持其通过二级市场集中竞价交易取得的公司股份，减持数量不超过14.88万股，即不超过 公司总股本的0.16%。减持价格将按照减持实际实施时的市场价格确定。 ...

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

上海毕得医药科技股份有限公司 证券代码：688073 证券简称：毕得医药 公告编号：2025-087 关于召开2025年第五次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2025年第五次临时股东会 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025年12月10日 至2025年12月10日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会召开当日的交易时间 段，即9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东会召开当日的9:15- 15:00。 （六）融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投票，应按照《上海证券交易 所科创板上市公司自律监管指引第1号 一 规范运作》等有关规定执行。 （七）涉及公开征集股东投票权 无 二、会议审议事项 本次股东会审议议案及投票股东类型 ● 股东会召开日期：2025年12月1 ...

（文章来源：证券日报） 证券日报网讯 11月24日晚间，毕得医药发布公告称，公司董事会于2025年11月24日召开了第二届董事 会第二十七次会议，审议通过了《关于补选公司第二届董事会非独立董事的议案》，董事会同意秦存亭 先生为公司第二届董事会非独立董事候选人，任期自股东会审议通过之日起至第二届董事会任期届满之 日止。 ...